FDA Grants Breakthrough Therapy Designation to Lenvima-Keytruda Combo for Advanced Endometrial Carcinoma

The U.S. Food and Drug Administration granted breakthrough therapy designation to an investigational combination of Eisai ’s Lenvima (lenvatinib) and Merck ‘s Keytruda (pembrolizumab) for the treatment of patients with a subset of advanced endometrial carcinoma . Specifically, the FDA’s decision covers patients with advanced and/or metastatic non-microsatellite instability […]

Leave a Reply